Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
09/13/2012 | 02:29pm CET

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502


Stephen Rea

+44 (0) 20 8047 5502


Sarah Spencer

+44 (0) 20 8047 5502


David Daley

+44 (0) 20 8047 5502


US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664


Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543


Tom Curry

+ 1 215 751 5419


Gary Davies

+ 44 (0) 20 8047 5503


James Dodwell

+ 44 (0) 20 8047 2406


Jeff McLaughlin

+ 1 215 751 7002


Ziba Shamsi

+ 44 (0) 20 8047 3289


GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
03/23GLAXOSMITHKLINE : GSK quits auction to buy $20bn Pfizer business
03/23GSK's two-drug HIV regimen wins European panel approval
03/23GLAXOSMITHKLINE : 26.6% Potential Upside Indicated by Liberum Capital
03/23GlaxoSmithKline Ends Talks for Pfizer Consumer-Healthcare Unit
03/23Glaxo in pole position in race for £14bn rival
03/22GLAXOSMITHKLINE : Studies in the Area of Chronic Obstructive Pulmonary Disease R..
03/22Glaxo in pole as Reckitt bails on Pfizer deal
03/22GLAXOSMITHKLINE : Researchers' Work from GlaxoSmithKline plc Focuses on Vaccines..
03/22GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Update Current Data on Clinic..
03/22GSK advances in Pfizer consumer health auction as Reckitt quits
More news
News from SeekingAlpha
03/23China Snaps Back, McMaster Leaves, Steve Wynn Exits The Scene (Wall Street Br.. 
03/23European advisory group backs ViiV Healthcare's two-drug HIV pill Juluca 
03/23WALL STREET BREAKFAST : China Strikes Back, McMaster Ouster 
03/23Glaxo's Shingrix OK'd in Europe and Japan 
03/23Glaxo pulls out of Pfizer asset auction 
Financials ( GBP)
Sales 2018 30 169 M
EBIT 2018 8 222 M
Net income 2018 4 079 M
Debt 2018 13 193 M
Yield 2018 6,28%
P/E ratio 2018 14,85
P/E ratio 2019 13,72
EV / Sales 2018 2,53x
EV / Sales 2019 2,45x
Capitalization 63 166 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 15,3  GBP
Spread / Average Target 20%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.11%351 935
PFIZER0.14%215 910
NOVARTIS-7.31%210 505
ROCHE HOLDING LTD.-12.21%198 996
MERCK AND COMPANY-3.82%147 455